Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure

Ádám Kiss, Ádám Menus, Katalin Tóth, Máté Déri, Dávid Sirok, Evelyn Gabri, Ales Belic, Gábor Csukly, István Bitter, Katalin Monostory

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The efficacy of aripiprazole therapy and the risk of adverse reactions are influenced by substantial inter-individual variability in aripiprazole metabolizing capacity. In vitro studies assigned the potential role in aripiprazole metabolism to CYP2D6 and CYP3A enzymes; therefore, the association between the steady-state aripiprazole plasma concentrations and patients’ CYP2D6 and CYP3A statuses (CYP2D6, CYP3A4, and CYP3A5 genotypes, and CYP3A4 expression) and/or co-medication with CYP function modifying medications has been investigated in 93 psychiatric patients on stable aripiprazole therapy. The patients’ CYP2D6 genotype had a major effect on aripiprazole plasma concentrations, whereas contribution of CYP3A genotypes and CYP3A4 expression to aripiprazole clearance were considered to be minor or negligible. The role of CYP3A4 expression in aripiprazole metabolism did not predominate even in the patients with nonfunctional CYP2D6 alleles. Furthermore, dehydroaripiprazole exposure was also CYP2D6 genotype-dependent. Dehydroaripiprazole concentrations were comparable with aripiprazole levels in patients with functional CYP2D6 alleles, and 35% or 22% of aripiprazole concentrations in patients with one or two non-functional CYP2D6 alleles, respectively. The concomitant intake of CYP2D6 inhibitors, risperidone, metoprolol, or propranolol was found to increase aripiprazole concentrations in patients with at least one wild-type CYP2D6*1 allele. Risperidone and 9-hydroxy-risperidone inhibited both dehydrogenation and hydroxylation of aripiprazole, whereas metoprolol and propranolol blocked merely the formation of the active dehydroaripiprazole metabolite, switching towards the inactivation pathways. Patients’ CYP2D6 genotype and co-medication with CYP2D6 inhibitors can be considered to be the major determinants of aripiprazole pharmacokinetics. Taking into account CYP2D6 genotype and co-medication with CYP2D6 inhibitors may improve the outcomes of aripiprazole therapy.

Original languageEnglish
Pages (from-to)71-82
Number of pages12
JournalEuropean archives of psychiatry and clinical neuroscience
Volume270
Issue number1
DOIs
Publication statusPublished - Feb 1 2020

Keywords

  • Aripiprazole therapy
  • CYP2D6 phenoconversion
  • Metoprolol
  • Propranolol
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure'. Together they form a unique fingerprint.

  • Cite this

    Kiss, Á., Menus, Á., Tóth, K., Déri, M., Sirok, D., Gabri, E., Belic, A., Csukly, G., Bitter, I., & Monostory, K. (2020). Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. European archives of psychiatry and clinical neuroscience, 270(1), 71-82. https://doi.org/10.1007/s00406-018-0975-2